INDIANAPOLIS — Cancer patients taking a drug made by Eli Lilly extended the amount of time they survived without their disease worsening, according to results of a study announced Sunday.
Lilly said results of the phase-3 “PARAMOUNT” study of the injected drug Alimta (pemetrexed) extended progression-free survival in patients with nonsquamous nonsmall-cell lung cancer. The study focused on continuation maintenance when one of the same drugs used as a first-line treatment for cancer is continued as maintenance therapy in an effort to control the disease.